Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Research & Development (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Research & Development data on record, last reported at $2.5 million in Q4 2025.

  • For Q4 2025, Research & Development rose 115.94% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $8.9 million, down 25.2%, while the annual FY2025 figure was $8.9 million, 25.21% down from the prior year.
  • Research & Development reached $2.5 million in Q4 2025 per VRCA's latest filing, up from $2.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $6.5 million in Q3 2023 and bottomed at -$10.3 million in Q4 2021.
  • Average Research & Development over 5 years is $2.8 million, with a median of $3.0 million recorded in 2022.
  • Peak YoY movement for Research & Development: soared 129.48% in 2022, then plummeted 78.06% in 2024.
  • A 5-year view of Research & Development shows it stood at -$10.3 million in 2021, then skyrocketed by 129.48% to $3.0 million in 2022, then soared by 75.69% to $5.3 million in 2023, then tumbled by 78.06% to $1.2 million in 2024, then surged by 115.94% to $2.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $2.5 million in Q4 2025, $2.2 million in Q3 2025, and $1.8 million in Q2 2025.